Stockscreener 앱 받기
7.25
1.12%
0.08
시장 영업 전:
7.25
전일 마감가:
$7.17
열려 있는:
$7.25
하루 거래량:
723.58K
Relative Volume:
0.53
시가총액:
$598.65M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-2.2943
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-11.59%
1개월 성능:
+3.57%
6개월 성능:
+24.78%
1년 성능:
-39.68%
1일 변동 폭
$7.17
$7.41
1주일 범위
$6.79
$8.3486
52주 변동 폭
$2.68
$13.24
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
7.25 | 592.05M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-10-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Replimune Stock Quote, Share Price, News and Analysis - Longbridge
REPL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz
Replimune to Present at Two Upcoming Investor Conferences - marketscreener.com
Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group, Inc. (REPL) Stock Analysis: A High-Potential Biotech Play with 67% Upside - DirectorsTalk Interviews
Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us
Replimune's Pivotal FDA Verdict Approaches - AD HOC NEWS
Market Leaders: Can Replimune Group Inc expand its profit margins2025 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Analyst Calls: Is Apyx Medical Corporation in accumulation or distribution phaseEarnings Miss & Real-Time Volume Analysis - baoquankhu1.vn
Replimune Shares Approach a Pivotal Regulatory Milestone - AD HOC NEWS
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha
What is Replimune Group Inc.’s market positionQuarterly Profit Summary & Precise Swing Trade Entry Alerts - mfd.ru
Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan
Institutional Confidence Surges in Replimune as Key Drug Review Looms - AD HOC NEWS
Replimune Group (NASDAQ:REPL) Trading Up 13.3%Here's Why - MarketBeat
Replimune rebounds despite analyst downgrades on FDA rejection - MSN
Replimune Group (NASDAQ:REPL) Stock Price Down 7.8%Here's What Happened - MarketBeat
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
How Replimune Group Inc. stock reacts to job market dataWeekly Trade Analysis & Risk Controlled Stock Pick Alerts - mfd.ru
Will Replimune Group Inc. stock outperform tech sector in 20252025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
Can Replimune Group Inc. be recession proofJuly 2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know - Finviz
Buybacks Report: Can Replimune Group Inc expand its profit marginsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Replimune Group, Inc. (REPL) stock news today: Live updates - Bitget
Is now the right time to enter Replimune Group Inc.Analyst Downgrade & Verified Entry Point Signals - mfd.ru
Insider Sell: Is Replimune Group Inc stock undervalued right now2025 Market Outlook & Daily Growth Stock Investment Tips - baoquankhu1.vn
Why Replimune Group Inc. stock is favored by pension fundsJuly 2025 Momentum & Entry Point Confirmation Signals - mfd.ru
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00 - MarketBeat
Piper Sandler Maintains 'Overweight' Rating for REPL, Raises PT to $14 | REPL Stock News - GuruFocus
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Replimune Secures Financial Runway Through 2027 - AD HOC NEWS
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price - MarketBeat
Replimune Group (REPL) to Release Quarterly Earnings on Wednesday - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - MSN
Replimune (REPL) Awaits FDA Approval for RP1 in Melanoma Treatme - GuruFocus
Replimune Group Q3 Earnings Summary & Key Takeaways - Benzinga
Replimune amends Hercules loan, strengthens funding runway - TipRanks
Earnings Summary: Replimune Group Q3 - Benzinga
Replimune Group, Inc. SEC 10-Q Report - TradingView
RP1 melanoma setback and SEC probe weigh on Replimune (NASDAQ: REPL) - Stock Titan
Earnings Breakdown: Replimune Group Q3 - Benzinga
Replimune Group Signs Loan and Security Agreement Amendment With Hercules Capital - TradingView
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dhingra Kapil | Director |
Dec 09 '25 |
Sale |
10.40 |
3,169 |
32,958 |
0 |
0.11%
6.00%
자본화:
|
볼륨(24시간):